Small Pharma To Present at the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
Live Presentation To Take Place at 9:30AM ET / 2:30PM GMT
April 27, 2022 – London, United Kingdom – Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, will present live at the KCSA Psychedelics Virtual Investor Conference at www.virtualinvestorconferences.com.
Details for the live presentation are as follows:
DATE: April 28, 2022
TIME: 9:30AM ET / 2:30PM GMT
The live virtual presentation by the Company will be followed by an opportunity for investors to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available after the event on the Company’s website.
To schedule a one-on-one meeting with Small Pharma’s management team, please contact KCSA Strategic Communications at SmallPharmaIR@kcsa.com.
Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelics with therapy for the treatment of mental health conditions, with a current focus on depression. Small Pharma initiated a clinical program into N,N-dimethyltryptamine (“DMT”) assisted psychotherapy in February 2021. This program includes a Phase I/IIa trial on the Company’s lead candidate alongside development of a robust pipeline of proprietary preclinical assets.
DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30 mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the most advanced clinical trial in commercial development for DMT-assisted psychotherapy in Major Depressive Disorder.
For further information contact:
Peter Rands Chief Executive Officer Email: firstname.lastname@example.org Tel: +44 (0)20 7112 9118
Media Relations Contacts:
McKenna Miller KCSA Strategic Communications Email: email@example.com Tel: +1 (949) 949-6585
Investor Relations Contacts:
Eric Ribner LifeSci Advisors Email: firstname.lastname@example.org Tel: +1 (646)-889-1200
Tim Regan/Adam Holdsworth KCSA Strategic Communications Email: email@example.com Tel: +1 (347) 487-6788
Rest of World
Donna Curran Hanover Communications Email: firstname.lastname@example.org
Tel: +44 (0)20 7400 4480
Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The UK Medicines and Healthcare products Regulatory Agency (“MHRA”) or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma’s performance and operations.
The TSX Venture Exchange (the “TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.